文献速递脊柱关节炎

最小疾病活动度是接受阿达木单抗治疗的银屑病关节炎患者治疗反应的稳定指标

Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

本研究基于多中心观察性研究数据,评估1684例活动性银屑病关节炎患者在接受阿达木单抗常规临床治疗24个月期间的最小疾病活动度(MDA)达标情况。第6个月时597例(35.5%)达到MDA,在继续治疗的患者中第24个月升至45.5%;MDA状态随时间保持稳定,第6个月达到MDA的患者中超过75%在后续访视中仍记录为MDA。

要点

  • 第6个月时35.5%的患者达到MDA,继续治疗者第24个月升至45.5%。
  • 第6个月达到MDA的患者中超过75%在后续访视中仍为MDA。
  • 疼痛是最难达到的单项标准,附着点炎是最易达到的单项标准。

核心结论

  • 在这个长病程患者的观察性队列中,MDA在24个月内提供了稳定且有效的临床状态评估。

研究设计与样本

  • 多中心观察性研究,纳入1684例在常规临床实践中启动阿达木单抗治疗并持续治疗至少6个月的活动性银屑病关节炎患者,评估24个月治疗期间MDA、单项MDA标准(按研究评估修改)及ACR反应。

主要发现

  • 第6个月时597例患者(35.5%)达到MDA,在继续治疗的患者中第24个月升至45.5%。
  • MDA状态随时间稳定,第6个月达到MDA的患者中超过75%在后续访视中记录为MDA。
  • 疼痛是最难达到的单项标准,附着点炎是最易达到的单项标准。
  • 基线时功能状态较高和压痛关节数较少可预测第6个月达到MDA。
  • 第6个月有ACR20反应的患者中约一半(51.5%)达到MDA。

关键数值与推荐

  • 第6个月MDA达标率35.5%(597/1684例),第24个月在继续治疗患者中为45.5%。
  • 第6个月有ACR20反应的患者中51.5%达到MDA。
  • 第6个月达到MDA的患者中超过75%在后续访视中仍为MDA。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to evaluate minimal disease activity (MDA) assessments in patients with PsA during routine clinical care. METHODS: We used data from a multicentre observational study of patients with active PsA who initiated treatment with adalimumab during routine clinical practice and continued treatment for at least 6 months to evaluate achievement of MDA, individual MDA criteria (modified to conform to study assessments) and ACR responses during 24 months of therapy. Pearson correlation coefficients were used to evaluate the association between MDA and individual criteria at month 6; regression models were used to determine the influence of baseline MDA criteria on achievement of MDA at month 6. RESULTS: A total of 1684 patients were included in these analyses; most had long-standing disease. MDA was achieved by 597 patients (35.5%) at month 6. This proportion increased to 45.5% at month 24 in patients remaining on therapy. MDA status was stable over time; >75% of patients with MDA at month 6 recorded MDA at subsequent visits. Pain was the most difficult individual criterion to achieve, and enthesitis was the least difficult. Higher functional status and fewer tender joints at baseline predicted achievement of MDA at month 6. About half of patients (51.5%) with an ACR20 response at month 6 achieved MDA. CONCLUSION: In this observational cohort of patients with long-standing disease, MDA provided a stable and valid assessment of clinical status over 24 months. TRIAL REGISTRATION: Clinicaltrials.gov, https://clinicaltrials.gov, NCT01111240.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Behrens F, Koehm M, Schwaneck EC, et al. Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab. Rheumatology (Oxford). 2018. PMID: 30010891. doi:10.1093/rheumatology/key203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。